As an example, vemurafenib does not produce high efficacy in BRAF V600 mutated colorectal cancer with an overall response rate of 5% [57], whereas vemurafenib is highly effective in BRAF V600 mutated non-small cell lung cancer [58] and melanoma [59] with an overall response rate around 45%. Here, BRAF is linked to non-small cell lung carcinoma.